MAHWAH, N.J.--(BUSINESS WIRE)--KORU Medical Systems, Inc. (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on...
New findings published in Alzheimer's & Dementia suggest blood biomarkers are expected to become the standard method for diagnosing Alzheimer's,...
Common Stock Will Begin Trading on Split-Adjusted Basis on March 14, 2025 TYLER, Texas--(BUSINESS WIRE)--NanoVibronix, Inc. (NASDAQ: NAOV) (“NanoVibronix” or...
NEW YORK--(BUSINESS WIRE)--InTandem Capital Partners (“InTandem Capital” or the “Firm”), a healthcare services-focused private equity firm, announced today that it...
VANCOUVER, BC, March 12, 2025 /PRNewswire/ -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or...
VANCOUVER, BC, March 12, 2025 /PRNewswire/ -- Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) (the "Company" or...
Content-Driven Program Brings Together Clinical Trial Stakeholders to Foster Knowledge Sharing and Collaboration in Cancer Research COLUMBIA, Md., March 12,...
Content-Driven Program Brings Together Clinical Trial Stakeholders to Foster Knowledge Sharing and Collaboration in Cancer Research COLUMBIA, Md., March 12,...
HAIFA, Israel, and CAMBRIDGE, England, March 12, 2025 /PRNewswire/ -- Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of...
HAIFA, Israel, and CAMBRIDGE, England, March 12, 2025 /PRNewswire/ -- Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of...
BEIJING, March 12, 2025 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated...
CARMEL, Ind., March 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Iolyx Therapeutics, a clinical-stage biotechnology company focused on the development of therapeutics...
Harnessing generative AI to develop targeted therapies for DNA damage response, including hard-to-treat central nervous system malignanciesVANCOUVER, British Columbia, March...
Largest shareholder, CK Life Sciences Int’l., (Holdings) Inc. agrees to conversion of debt into equity, removing all existing debt from...
Encouraging Safety Profile Supports Progression Toward First Dual-Administration of Selective A2A and A2B Antagonists in PatientsDOVER, Del., March 12, 2025...
GAITHERSBURG, Md. and BASEL, Switzerland, March 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS), a leading public health...
Oral presentations will highlight the implementation of a validated research-use plasma pTau217 assay in the participant screening process for the...
Late-breaking clinical and first translational data from BOND-003 Cohort C will be presentedIRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) --...
New Cross-Regimen Analysis of HEALEY ALS Platform Trial Shows Significant Survival AdvantageSALT LAKE CITY, March 12, 2025 (GLOBE NEWSWIRE) --...